Clinical Trials
86 trialsHydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory
Northwestern University
Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
SAFIR-ABC10
UNICANCER
Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer
National Cancer Institute (NCI)
Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement
Eastern Cooperative Oncology Group
Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer
Massachusetts General Hospital
OCEANII
Pierre Fabre Medicament
NAUTICALCRC
Pierre Fabre Medicament
Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
National Cancer Institute (NCI)
SuRage-EB
SRH Wald-Klinikum Gera GmbH
Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases
M.D. Anderson Cancer Center
Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer
Providence Health & Services
UK-EnBiRiM
Pierre Fabre Ltd
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
Pfizer
The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials
Pfizer
SEAMARK
Pfizer
Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL
National Institutes of Health Clinical Center (CC)
BEPCOME-MB
UNICANCER
HERKULES-3
Erasca, Inc.
An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer
Pfizer
Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy
M.D. Anderson Cancer Center
PORTSIDE
Pfizer
Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma
H. Lee Moffitt Cancer Center and Research Institute
COLUMBUS
Pfizer
ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma
University of Kentucky
Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer
Alliance for Clinical Trials in Oncology
Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)
Pfizer
BRICKET
Gruppo Oncologico del Nord-Ovest
Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma
M.D. Anderson Cancer Center
DETERMINE
University of Utah
ENCO-BRAF
Intergroupe Francophone de Cancerologie Thoracique
NeoBRAF
AIO-Studien-gGmbH
ENCEFALO
Grupo Español Multidisciplinar de Melanoma
REFISH
Vall d'Hebron Institute of Oncology
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
SWOG Cancer Research Network
NEORAF
Federation Francophone de Cancerologie Digestive
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
Pfizer
ZN-c3 in Adult Participants With Metastatic Colorectal Cancer
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
EBIN
European Organisation for Research and Treatment of Cancer - EORTC
MK3475-C01
Sheba Medical Center
EBRAIN-MEL
Grupo Español Multidisciplinar de Melanoma
OCEANMIST
Pfizer
ECLYPse
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
BEAVER
University Health Network, Toronto
StrataPATH
Strata Oncology
BRAVE
Vall d'Hebron Institute of Oncology
BRAF
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma
Pfizer